Paul Joseph Barreira, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Soccer | 4 | 2019 | 109 | 1.350 |
Why?
|
| Employment, Supported | 6 | 2011 | 29 | 1.120 |
Why?
|
| Rehabilitation, Vocational | 3 | 2011 | 86 | 0.710 |
Why?
|
| Mental Disorders | 15 | 2012 | 6378 | 0.580 |
Why?
|
| Community Mental Health Services | 5 | 2010 | 405 | 0.560 |
Why?
|
| Leg Injuries | 1 | 2016 | 188 | 0.540 |
Why?
|
| Athletic Injuries | 3 | 2019 | 1117 | 0.470 |
Why?
|
| Rehabilitation | 1 | 2010 | 138 | 0.380 |
Why?
|
| Desensitization, Immunologic | 1 | 2014 | 461 | 0.370 |
Why?
|
| Mental Health Services | 6 | 2008 | 1575 | 0.370 |
Why?
|
| Ticlopidine | 1 | 2014 | 910 | 0.340 |
Why?
|
| Personal Autonomy | 1 | 2008 | 309 | 0.290 |
Why?
|
| Drug Hypersensitivity | 1 | 2014 | 845 | 0.290 |
Why?
|
| Patient Participation | 3 | 2010 | 1424 | 0.260 |
Why?
|
| Community Mental Health Centers | 2 | 2001 | 100 | 0.250 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 4960 | 0.240 |
Why?
|
| Choice Behavior | 2 | 2008 | 792 | 0.240 |
Why?
|
| Social Support | 1 | 2011 | 2088 | 0.210 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 2963 | 0.210 |
Why?
|
| Mumps virus | 1 | 2020 | 29 | 0.210 |
Why?
|
| Mumps | 1 | 2020 | 57 | 0.200 |
Why?
|
| Contract Services | 1 | 1999 | 95 | 0.190 |
Why?
|
| Certification | 3 | 2006 | 401 | 0.170 |
Why?
|
| Schizophrenic Psychology | 2 | 2006 | 1681 | 0.170 |
Why?
|
| Jogging | 1 | 2016 | 18 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3797 | 0.170 |
Why?
|
| Self-Injurious Behavior | 2 | 2012 | 411 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2010 | 9337 | 0.160 |
Why?
|
| Program Evaluation | 2 | 2010 | 2560 | 0.150 |
Why?
|
| Genome, Viral | 1 | 2020 | 697 | 0.150 |
Why?
|
| Acceleration | 1 | 2016 | 173 | 0.150 |
Why?
|
| Muscle Strength | 1 | 2019 | 571 | 0.140 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 276 | 0.140 |
Why?
|
| Peer Group | 2 | 2011 | 630 | 0.130 |
Why?
|
| Propranolol | 3 | 1984 | 528 | 0.130 |
Why?
|
| Professional-Patient Relations | 2 | 2010 | 729 | 0.130 |
Why?
|
| Motor Skills | 1 | 2016 | 527 | 0.130 |
Why?
|
| Life Expectancy | 1 | 1999 | 1105 | 0.120 |
Why?
|
| Immobilization | 1 | 2014 | 251 | 0.120 |
Why?
|
| Motivation | 2 | 2005 | 1863 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2001 | 7631 | 0.120 |
Why?
|
| Task Performance and Analysis | 1 | 2016 | 837 | 0.110 |
Why?
|
| Students | 2 | 2012 | 1543 | 0.110 |
Why?
|
| Psychotic Disorders | 4 | 2004 | 2669 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2000 | 949 | 0.110 |
Why?
|
| Anthropometry | 1 | 2016 | 1456 | 0.110 |
Why?
|
| Insurance, Psychiatric | 1 | 2010 | 70 | 0.110 |
Why?
|
| Massachusetts | 6 | 2008 | 8920 | 0.110 |
Why?
|
| Muscular Atrophy | 1 | 2014 | 354 | 0.100 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 1707 | 0.100 |
Why?
|
| Alcoholic Intoxication | 1 | 2011 | 188 | 0.100 |
Why?
|
| Adult | 25 | 2019 | 211400 | 0.100 |
Why?
|
| Schizophrenia | 4 | 2006 | 6549 | 0.090 |
Why?
|
| Health Services Research | 2 | 2009 | 1858 | 0.090 |
Why?
|
| Akathisia, Drug-Induced | 3 | 1984 | 74 | 0.090 |
Why?
|
| Psychiatry | 1 | 1999 | 1502 | 0.090 |
Why?
|
| Muscle Proteins | 1 | 2014 | 1266 | 0.090 |
Why?
|
| Psychomotor Agitation | 3 | 1984 | 279 | 0.090 |
Why?
|
| Substance-Related Disorders | 2 | 2004 | 4253 | 0.090 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2010 | 339 | 0.080 |
Why?
|
| Medicaid | 2 | 2004 | 2479 | 0.080 |
Why?
|
| Male | 27 | 2019 | 352465 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 1501 | 0.080 |
Why?
|
| Humans | 43 | 2020 | 686663 | 0.080 |
Why?
|
| Emotions | 1 | 2018 | 2319 | 0.080 |
Why?
|
| Psychotropic Drugs | 1 | 1992 | 906 | 0.080 |
Why?
|
| Health Policy | 1 | 1999 | 2596 | 0.080 |
Why?
|
| Models, Organizational | 2 | 2000 | 586 | 0.070 |
Why?
|
| Universities | 1 | 2011 | 869 | 0.070 |
Why?
|
| Vertigo | 1 | 2006 | 162 | 0.070 |
Why?
|
| Self-Help Groups | 1 | 2006 | 202 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2010 | 2912 | 0.070 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 1994 | 1556 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 3 | 2001 | 2306 | 0.070 |
Why?
|
| Thirst | 1 | 1984 | 34 | 0.070 |
Why?
|
| Random Allocation | 1 | 2009 | 2507 | 0.070 |
Why?
|
| Suicidal Ideation | 1 | 2012 | 990 | 0.070 |
Why?
|
| Paranoid Disorders | 1 | 1983 | 48 | 0.070 |
Why?
|
| Body Composition | 1 | 2014 | 2381 | 0.070 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1984 | 69 | 0.070 |
Why?
|
| Metoprolol | 1 | 1984 | 95 | 0.070 |
Why?
|
| Employment | 1 | 2010 | 1073 | 0.070 |
Why?
|
| Drinking Behavior | 1 | 1984 | 115 | 0.060 |
Why?
|
| Antidepressive Agents | 2 | 1988 | 2764 | 0.060 |
Why?
|
| Hospitals, Psychiatric | 2 | 2001 | 339 | 0.060 |
Why?
|
| Research Subjects | 1 | 2005 | 242 | 0.060 |
Why?
|
| New York City | 2 | 2007 | 655 | 0.060 |
Why?
|
| Paroxetine | 1 | 2003 | 174 | 0.060 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 724 | 0.060 |
Why?
|
| Suicide | 1 | 2012 | 1448 | 0.060 |
Why?
|
| Exercise | 1 | 2018 | 5078 | 0.060 |
Why?
|
| Assertiveness | 1 | 2001 | 19 | 0.060 |
Why?
|
| Group Homes | 1 | 2001 | 13 | 0.060 |
Why?
|
| Dementia | 1 | 1994 | 1984 | 0.060 |
Why?
|
| Commitment of Mentally Ill | 1 | 2001 | 89 | 0.060 |
Why?
|
| Program Development | 1 | 2008 | 1334 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2008 | 1162 | 0.050 |
Why?
|
| Bereavement | 1 | 2004 | 242 | 0.050 |
Why?
|
| Benchmarking | 2 | 2010 | 880 | 0.050 |
Why?
|
| Data Collection | 1 | 2010 | 3321 | 0.050 |
Why?
|
| Antipsychotic Agents | 4 | 1992 | 3015 | 0.050 |
Why?
|
| Health Surveys | 1 | 2011 | 4119 | 0.050 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2019 | 44 | 0.050 |
Why?
|
| Female | 23 | 2018 | 375459 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2006 | 1118 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2003 | 766 | 0.050 |
Why?
|
| Proprioception | 1 | 2019 | 124 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 19308 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 489 | 0.040 |
Why?
|
| Bipolar Disorder | 5 | 1999 | 4998 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2006 | 1774 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2018 | 653 | 0.040 |
Why?
|
| Public Health Administration | 1 | 1999 | 251 | 0.040 |
Why?
|
| Cooperative Behavior | 2 | 2007 | 1586 | 0.040 |
Why?
|
| United States | 9 | 2020 | 65579 | 0.040 |
Why?
|
| Placebos | 1 | 2001 | 1791 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2011 | 3649 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 2001 | 811 | 0.040 |
Why?
|
| Depressive Disorder | 2 | 1988 | 3893 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2001 | 859 | 0.040 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2003 | 1425 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 15407 | 0.030 |
Why?
|
| Body Fluid Compartments | 1 | 2014 | 51 | 0.030 |
Why?
|
| Depressive Disorder, Major | 2 | 2003 | 4299 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 33186 | 0.030 |
Why?
|
| Life Change Events | 2 | 2012 | 933 | 0.030 |
Why?
|
| Middle Aged | 12 | 2011 | 216468 | 0.030 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2012 | 152 | 0.030 |
Why?
|
| Teaching | 1 | 2001 | 1213 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1992 | 423 | 0.030 |
Why?
|
| Aged | 6 | 2014 | 162271 | 0.030 |
Why?
|
| Resistance Training | 1 | 2014 | 157 | 0.030 |
Why?
|
| Solutions | 1 | 1992 | 441 | 0.030 |
Why?
|
| Phylogeny | 1 | 2020 | 2863 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2003 | 2006 | 0.030 |
Why?
|
| Patient Care Team | 2 | 2001 | 2596 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2014 | 563 | 0.030 |
Why?
|
| Biological Availability | 1 | 1992 | 404 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2020 | 1996 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2005 | 3296 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 1999 | 2527 | 0.030 |
Why?
|
| Length of Stay | 2 | 2001 | 6241 | 0.030 |
Why?
|
| Knee Joint | 1 | 2019 | 1538 | 0.030 |
Why?
|
| Homosexuality | 1 | 2011 | 276 | 0.030 |
Why?
|
| Social Adjustment | 1 | 2012 | 672 | 0.030 |
Why?
|
| Atrophy | 1 | 1994 | 1447 | 0.020 |
Why?
|
| Adolescent | 7 | 2019 | 84957 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2004 | 8882 | 0.020 |
Why?
|
| Young Adult | 4 | 2019 | 56052 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 5761 | 0.020 |
Why?
|
| Severity of Illness Index | 3 | 2006 | 16227 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 39737 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2014 | 885 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2001 | 2479 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1994 | 1939 | 0.020 |
Why?
|
| Cause of Death | 1 | 1999 | 3582 | 0.020 |
Why?
|
| Anger | 1 | 2011 | 392 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2014 | 969 | 0.020 |
Why?
|
| Vaccination | 1 | 2020 | 2487 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 5044 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 788 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 21640 | 0.020 |
Why?
|
| Parkinson Disease, Secondary | 2 | 1984 | 132 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2011 | 67320 | 0.020 |
Why?
|
| Lithiasis | 1 | 2006 | 14 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2007 | 323 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2009 | 430 | 0.020 |
Why?
|
| Pilot Projects | 1 | 1999 | 7791 | 0.020 |
Why?
|
| Researcher-Subject Relations | 1 | 2005 | 18 | 0.020 |
Why?
|
| Haloperidol | 2 | 1984 | 389 | 0.020 |
Why?
|
| Amantadine | 1 | 1984 | 58 | 0.020 |
Why?
|
| Thioridazine | 1 | 1984 | 37 | 0.020 |
Why?
|
| Perphenazine | 1 | 1984 | 37 | 0.020 |
Why?
|
| Genotype | 1 | 2020 | 13073 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1992 | 3975 | 0.020 |
Why?
|
| Doxepin | 1 | 1983 | 19 | 0.020 |
Why?
|
| Phenelzine | 1 | 1983 | 33 | 0.020 |
Why?
|
| Vestibular Diseases | 1 | 2006 | 206 | 0.020 |
Why?
|
| Imipramine | 1 | 1983 | 111 | 0.020 |
Why?
|
| Amitriptyline | 1 | 1983 | 119 | 0.020 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1983 | 172 | 0.020 |
Why?
|
| Water-Electrolyte Balance | 1 | 1984 | 351 | 0.020 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2005 | 260 | 0.020 |
Why?
|
| Body Weight | 1 | 2014 | 4804 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 1446 | 0.010 |
Why?
|
| Hospitals, State | 1 | 2001 | 33 | 0.010 |
Why?
|
| Mothers | 1 | 2012 | 1978 | 0.010 |
Why?
|
| Licensure, Hospital | 1 | 2001 | 3 | 0.010 |
Why?
|
| Hospitalization | 1 | 2001 | 9304 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 1992 | 2371 | 0.010 |
Why?
|
| Hospitals, Private | 1 | 2001 | 67 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 2003 | 411 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2014 | 3232 | 0.010 |
Why?
|
| Delusions | 1 | 1983 | 293 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2004 | 382 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 2006 | 808 | 0.010 |
Why?
|
| Restless Legs Syndrome | 1 | 1983 | 207 | 0.010 |
Why?
|
| Hyponatremia | 1 | 1984 | 311 | 0.010 |
Why?
|
| Hospitals, Public | 1 | 2001 | 195 | 0.010 |
Why?
|
| Respiratory Sounds | 1 | 1984 | 688 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2007 | 2659 | 0.010 |
Why?
|
| Risk | 1 | 2012 | 9915 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2004 | 768 | 0.010 |
Why?
|
| Risk Factors | 2 | 2012 | 69278 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 1624 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2006 | 2330 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2006 | 1646 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1984 | 1250 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 1943 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 13444 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1983 | 1904 | 0.010 |
Why?
|
| Demography | 1 | 2001 | 1583 | 0.010 |
Why?
|
| Sex Factors | 1 | 2011 | 10926 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13807 | 0.010 |
Why?
|
| Mutation | 1 | 2020 | 28848 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 4014 | 0.010 |
Why?
|
| Neurons | 1 | 1994 | 9331 | 0.010 |
Why?
|
| Acute Disease | 1 | 1984 | 7202 | 0.010 |
Why?
|
| Hippocampus | 1 | 2006 | 3587 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2001 | 2878 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2006 | 6814 | 0.010 |
Why?
|
| Time Factors | 2 | 2006 | 42271 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 3396 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1983 | 2594 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 8070 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2006 | 3942 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10766 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 2842 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2006 | 6421 | 0.010 |
Why?
|
| Health Status | 1 | 2004 | 4011 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1994 | 20409 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 12525 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 10648 | 0.010 |
Why?
|
| Insurance Coverage | 1 | 2001 | 1795 | 0.010 |
Why?
|
| Research Design | 1 | 2005 | 5835 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 11866 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 9114 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 21684 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1984 | 8529 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1983 | 13603 | 0.010 |
Why?
|
| Brain | 1 | 1994 | 24202 | 0.010 |
Why?
|
| Medicare | 1 | 2001 | 5077 | 0.000 |
Why?
|
| Drug Tolerance | 1 | 1984 | 400 | 0.000 |
Why?
|
| Lithium | 1 | 1984 | 620 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1983 | 1737 | 0.000 |
Why?
|